Plasma sTNFRI levels correlate with onset of IPS and response to therapy. Plasma sTNFRI levels were analyzed from samples collected at the time of IPS diagnosis and were retrospectively categorized as responders (IPS-Dx [Resp]) or nonresponders (IPS-Dx [NR]) based on the ultimate outcome during study therapy. For responding patients, data are also provided at the end of study therapy (IPS-post [Resp]). Levels of sTNFRI are elevated at the time of IPS and return toward baseline in patients who respond to combination therapy. Data are expressed as concentration in pg/mL for each individual sample. Significant differences between groups are shown; n = 7 to 14 per group.